MA-TA-ASSOCIATES
8.2.2021 17:02:06 CET | Business Wire | Press release
TA Associates, a leading global growth private equity firm, today announced that it has entered exclusive negotiations to make a majority growth investment in DL Software, a leading France-based group of enterprise resource planning (ERP) software providers. Current DL Software majority shareholder 21 Invest France, as well as company founders and management, would each retain a stake in the business following TA’s investment. The envisaged transaction, which is currently under review by representatives of the company’s employees, is expected to close in the second quarter of 2021, subject to customary approvals. Financial terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005585/en/
“DL Software has become a leading B2B software player in France through a longstanding strategy of acquiring and growing highly-verticalized ERP vendors,” said Maxime Cancre, a Principal at TA Associates who would join the DL Software Board of Directors. “We are pleased to announce this prospective investment and look forward to partnering with DL Software management and our fellow investors in actively seeking new growth opportunities for the company.”
“It is a pleasure to have the opportunity to welcome TA Associates as an investor in DL Software,” said Jacques Ollivier, President of DL Software. “DL has developed significantly in recent years, both organically and inorganically, and we are excited to combine our know-how with TA’s software investing experience with an aim to deliver sustained strong performance for years to come. With the support of our investors, DL will continue to seek additional acquisition opportunities in France and may consider other markets in Europe.”
“We have been very impressed with the development of DL Software under the ownership of 21 Invest France and its co-investors, Amundi Private Equity Funds and Swen Capital Partners, and the leadership of Jacques Ollivier,” said Patrick Sader, a Managing Director at TA Associates who would also join the DL Software Board of Directors. “DL Software enjoys a high-quality revenue model and the French ERP market is large, so we see meaningful expansion opportunities for the company. We are very excited to embark on this journey.”
“I join the DL Software team in welcoming TA as a future investor,” said Stephane Perriquet, Managing Partner at 21 Invest France. “We have enjoyed collaborating with DL Software, helping to grow the company’s market share over the past several years, and look forward to this next phase in the continuing evolution of the company.”
De Pardieu Brocas Maffei served as legal counsel, DC Advisory as M&A advisor and Eight Advisory as financial advisors to DL Software and its shareholders. Latham & Watkins served as legal counsel, Bryan Garnier as M&A advisor and KPMG as financial and tax advisor to TA Associates. Jausserand Audouard and Oloryn advised management.
About DL Software
Founded in 2003, DL Software is a specialist in business ERP. The group has 13 independent and specialized companies whose solutions address more than 30 vertical sectors, including health, insurance, retail, trading, real estate and tourism. Since its founding, DL Software has realized an average annual growth rate of more than 10%. For more information, please visit www.dlsoftware.fr
.
About TA Associates
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. DL Software will be TA’s eleventh investment in France since 2009. More information about TA Associates can be found at www.ta.com
.
About 21 Invest
An active shareholder alongside management teams, 21 Invest supports companies based in France, Italy and Poland and accompanies them into new stages of development. Over the last 29 years, 21 Invest has realized more than 105 investments. In France, 21 Invest invests in growing and resilient SMEs in the healthcare, business services, and technology sectors. More information about 21 Invest can be found at www.21invest.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom